# Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

> **NCT07665190** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Hypopharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Becotatug Vedotin and Pucotenlimab

## Key facts

- **NCT ID:** NCT07665190
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665190, "Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*